Related Experiment Videos
An orally administered microcapsule system for treating chronic renal failure patients
Applied Biochemistry and Biotechnology
|January 1, 1984
Summary
Ingestible adsorbents, like urease and zirconium phosphate (UZP) microcapsules, show promise for removing uremic toxins. Studies in a dog model suggest potential as adjunctive therapy for chronic kidney disease patients.
Area of Science:
- Nephrology
- Gastroenterology
- Biomaterials
Background:
- Chronic uremia involves the buildup of toxic metabolites.
- Current treatments for chronic uremia have limitations.
- Ingestible adsorbents offer a novel therapeutic approach.
Purpose of the Study:
- To investigate the efficacy of urease and zirconium phosphate (UZP) microcapsules.
- To evaluate the removal of uremic metabolites from the GI tract.
- To assess the potential of a dog model for studying uremic toxins.
Main Methods:
- Development of a dog model simulating chronic uremia.
- Perfusion studies to measure metabolite concentrations and flux rates.
- Administration of UZP microcapsules to assess efficacy.
Main Results:
- Urea and creatinine were effectively removed from the GI tract using ingestible adsorbents.
- The reduction of blood urea nitrogen was limited by the ammonium binding capacity of zirconium phosphate.
- The dog model demonstrated utility in studying uremic toxins like guanidinosuccinic acid.
Conclusions:
- Ingestible adsorbents can remove key uremic metabolites from the GI tract.
- UZP microcapsules show potential as an adjunctive therapy for chronic renal failure.
- Further clinical studies are warranted to confirm therapeutic benefits.